Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 3, 2017
Previous Article Next Article

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Author affiliations

Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

Graphical abstract: Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 19 Nov 2016, accepted on 09 Jan 2017 and first published on 26 Jan 2017


Article type: Research Article
DOI: 10.1039/C6MD00643D
Citation: Med. Chem. Commun., 2017,8, 621-624
  •   Request permissions

    Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

    L. Luo, X. Fan, Y. Li, X. Peng, Y. Ji, W. W. Hsiao, L. Liu, E. L. Leung and X. Yao, Med. Chem. Commun., 2017, 8, 621
    DOI: 10.1039/C6MD00643D

Search articles by author